Wall Street analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to report earnings per share (EPS) of $0.16 for the current quarter, Zacks reports. Two analysts have issued estimates for American Renal Associates’ earnings. The lowest EPS estimate is $0.13 and the highest is $0.18. American Renal Associates posted earnings per share of $0.26 during the same quarter last year, which indicates a negative year-over-year growth rate of 38.5%. The business is scheduled to issue its next earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that American Renal Associates will report full-year earnings of $0.57 per share for the current fiscal year, with EPS estimates ranging from $0.54 to $0.59. For the next financial year, analysts forecast that the company will post earnings of $0.74 per share, with EPS estimates ranging from $0.70 to $0.79. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow American Renal Associates.

American Renal Associates (NYSE:ARA) last released its quarterly earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The firm had revenue of $187.71 million for the quarter, compared to the consensus estimate of $194.60 million. American Renal Associates had a positive return on equity of 15.80% and a negative net margin of 2.15%. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS.

ARA has been the topic of several analyst reports. Leerink Swann reiterated an “outperform” rating and set a $17.00 target price (down from $22.00) on shares of American Renal Associates in a research report on Tuesday, November 21st. Zacks Investment Research downgraded American Renal Associates from a “buy” rating to a “hold” rating in a research report on Friday, November 17th. Finally, SunTrust Banks set a $18.00 target price on American Renal Associates and gave the company a “buy” rating in a research report on Sunday, October 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $17.75.

American Renal Associates (NYSE:ARA) traded up $0.14 during mid-day trading on Thursday, hitting $14.48. The stock had a trading volume of 153,648 shares, compared to its average volume of 150,006. The stock has a market cap of $446.11, a P/E ratio of 21.16, a P/E/G ratio of 1.25 and a beta of 4.29. American Renal Associates has a 52-week low of $9.91 and a 52-week high of $24.35. The company has a current ratio of 1.16, a quick ratio of 1.13 and a debt-to-equity ratio of 3.57.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARA. Van Berkom & Associates Inc. lifted its position in American Renal Associates by 490.5% during the third quarter. Van Berkom & Associates Inc. now owns 2,191,863 shares of the company’s stock valued at $32,812,000 after purchasing an additional 1,820,649 shares in the last quarter. Vanguard Group Inc. lifted its position in American Renal Associates by 11.6% during the first quarter. Vanguard Group Inc. now owns 928,768 shares of the company’s stock valued at $15,678,000 after purchasing an additional 96,196 shares in the last quarter. TimesSquare Capital Management LLC lifted its position in American Renal Associates by 6.7% during the second quarter. TimesSquare Capital Management LLC now owns 1,290,200 shares of the company’s stock valued at $23,933,000 after purchasing an additional 80,650 shares in the last quarter. JPMorgan Chase & Co. lifted its position in American Renal Associates by 2,089.4% during the second quarter. JPMorgan Chase & Co. now owns 72,250 shares of the company’s stock valued at $1,340,000 after purchasing an additional 68,950 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in American Renal Associates by 303.9% during the third quarter. Dimensional Fund Advisors LP now owns 50,027 shares of the company’s stock valued at $749,000 after purchasing an additional 37,641 shares in the last quarter. Institutional investors own 93.27% of the company’s stock.

WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/zacks-brokerages-anticipate-american-renal-associates-holdings-inc-ara-will-announce-earnings-of-0-16-per-share.html.

About American Renal Associates

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.